Experimental antibody drug shows promise for Hard-to-Treat lymphoma

NCT ID NCT05927558

Completed Disease control Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study looks at how well the drug glofitamab works in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are tracking how many patients achieve a complete response after receiving glofitamab through a compassionate use program. The goal is to see if this therapy can help people who have few other options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glofitamab
What this could lead to: If successful, this could show that glofitamab is an effective treatment option for patients with hard-to-treat B-cell lymphoma who have few alternatives.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. The drug is given through a compassionate use program, meaning patients are very sick and outcomes may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON HODGKIN LYMPHOMA REFRACTORY LYMPHOMA RELAPSE

Contacts and locations

Show contact details

Locations

Ematologia Istituto Nazionale Tumori

Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.